IPHYF News and Press, Innate Pharma - Class A From 04/28/25

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET ® program in autoimmune indications, and more Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate...

Innate to regain its rights on CD123 targeting ANKET ® SAR443579 (SAR’579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions Sanofi to continue...

Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its annual general meeting of shareholders (“ AGM ”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Lumi...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on ...

2025-03-27 16:49:38 ET Innate Pharma S.A. (IPHA) Q4 2024 Earnings Conference Call March 27, 2025, 09:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard...

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024 ...

IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors wit...